Patents Examined by Larry R. Helms
  • Reagents and methods for inducing an immune response to prostate specific antigen
    Patent number: 7579445
    Abstract: The invention is an apparatus and method for the treatment of prostate cancer, and involves administering an antibody that specifically binds with prostate antigen.
    Type: Grant
    Filed: October 14, 2004
    Date of Patent: August 25, 2009
    Assignee: AltaRex Medical Corp.
    Inventors: Beatrice Leveugle, Ragupathy Madiyalakan, Antoine A. Noujaim, Birgit C. Schultes
  • Methods for the detection of cervical cancer
    Patent number: 7579160
    Abstract: Compositions and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly lung cancer.
    Type: Grant
    Filed: August 19, 2004
    Date of Patent: August 25, 2009
    Assignee: Corixa Corporation
    Inventors: Chaitanya S. Bangur, Barbara K. Zehentner-Wilkinson
  • DADD, death activator death domain protein
    Patent number: 7576178
    Abstract: Polynucleotides encoding DADD protein are also disclosed, along with vectors, host cells, and methods of making DADD protein. Methods of identifying inhibitors of DADD death domain binding and inhibitors identified by such methods are also disclosed.
    Type: Grant
    Filed: May 13, 2005
    Date of Patent: August 18, 2009
    Assignee: Genetics Institute, LLC
    Inventors: Jean-Baptiste Telliez, Lih-Ling Lin
  • Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
    Patent number: 7575748
    Abstract: The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anti-ErbB receptor antibody-maytansinoid conjugates.
    Type: Grant
    Filed: July 17, 2006
    Date of Patent: August 18, 2009
    Assignee: Genentech, Inc.
    Inventors: Sharon Erickson, Ralph Schwall, Mark Sliwkowski, Walter Blattler
  • Polypeptide and gene encoding the same
    Patent number: 7575922
    Abstract: A polypeptide having the amino acid sequence as set forth in SEQ ID NO: 2, 4, or 6, a DNA encoding the same, and an antibody against said polypeptide, and the use thereof. The above amino acid sequence has a homology with chondromodulin-I that has an effect of controlling the growth and differentiation of chondrocytes and inhibiting angiogenesis.
    Type: Grant
    Filed: August 4, 2005
    Date of Patent: August 18, 2009
    Assignee: Teijin Limited
    Inventors: Kei Yamana, Yukimi Nagasawa, Hitoshi Wada, Yoshinori Kasahara
  • Tumor suppressor Killin
    Patent number: 7576191
    Abstract: The present invention relates to a new tumor suppressor, designated Killin. Also described are diagnostic and therapeutic uses of the Killin protein and the killin gene, alone or in combination with traditional cancer therapies.
    Type: Grant
    Filed: September 11, 2006
    Date of Patent: August 18, 2009
    Assignee: Vanderbilt University
    Inventors: Peng Liang, Yong-jig Cho
  • Antibodies to oncostatin M receptor
    Patent number: 7572896
    Abstract: The invention provides characterization of the disease and cancer-associated antigen, OSM-R.beta. The invention also provides modulators of OSM-R.beta, including a family of monoclonal antibodies that bind to antigen OSM-R.beta, and methods of diagnosing and treating various human cancers and diseases associated with OSM-R.beta.
    Type: Grant
    Filed: February 3, 2006
    Date of Patent: August 11, 2009
    Assignee: Raven biotechnologies, Inc.
    Inventors: Jennie P. Mather, Penelope E. Roberts
  • Death associated proteins, and THAP1 and PAR4 pathways in apoptosis control
    Patent number: 7572886
    Abstract: The invention relates to genes and proteins of the THAP (THanatos (death)-Associated Protein) family comprising a THAP domain, and their use in diagnostics, treatment of disease, and in the identification of molecules for the treatment of disease. The invention also relates to the Par4 protein and SLC chemokine pathways, including the interaction of Par4 and SLC with THAP family proteins, and the recruitment and localization of Par4 to PML nuclear bodies.
    Type: Grant
    Filed: December 10, 2002
    Date of Patent: August 11, 2009
    Assignee: Centre National de la Recherche Scientifique
    Inventors: Jean-Philippe Girard, Francois Amalric, Myriam Roussigne, Thomas Clouaire
  • Anti-PECAM therapy for metastasis suppression
    Patent number: 7572443
    Abstract: The invention provides novel compositions, methods, kits, and uses thereof relating to antimetastatic agents useful for treating neoplastic diseases.
    Type: Grant
    Filed: November 12, 2004
    Date of Patent: August 11, 2009
    Assignee: California Pacific Medical Center
    Inventor: Robert Debs
  • Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of lung cancer
    Patent number: 7569662
    Abstract: Novel markers for lung cancer that are both sensitive and accurate. These markers are overexpressed in lung cancer specifically, as opposed to normal lung tissue. The measurement of these markers, alone or in combination, in patient samples provides information that the diagnostician can correlate with a probable diagnosis of lung cancer. The markers of the present invention, alone or in combination, show a high degree of differential detection between lung cancer and non-cancerous states.
    Type: Grant
    Filed: January 27, 2005
    Date of Patent: August 4, 2009
    Assignee: Compugen Ltd
    Inventors: Sarah Pollock, Zurit Levine, Amit Novik, Dvir Dahary, Rotem Sorek, Amir Toporik, Shirley Sameah-Greenwald, Osnat Sella-Tavor, Alexander Diber, Gad S. Cojocaru, Michal Ayalon-Soffer, Shira Walach, Pinchas Akiva, Naomi Keren, Ronen Shemesh
  • Humanised antibodies
    Patent number: 7566771
    Abstract: CDR-grafted antibody heavy and light chains comprise acceptor framework and donor antigen binding regions, the heavy chains comprising donor residues at at least one of positions (6, 23) and/or (24, 48) and/or (49, 71) and/or (73, 75) and/or (76) and/or (78) and (88) and/or (91). The CDR-grafted light chains comprise donor residues at at least one of positions (1) and/or (3) and (46) and/or (47) or at at least one of positions (46, 48, 58) and (71). The CDR-grafted antibodies are preferably humanized antibodies, having non human, e.g. rodent, donor and human acceptor frameworks, and may be used for in vivo therapy and diagnosis. A generally applicable protocol is disclosed for obtaining CDR-grafted antibodies.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: July 28, 2009
    Assignee: Celltech R&D Limited
    Inventors: John Robert Adair, Diljeet Singh Athwal, John Spencer Emtage
  • Humanized collagen antibodies and related methods
    Patent number: 7566770
    Abstract: The invention provides an antibody, or functional fragment thereof, a grafted antibody, or functional fragment thereof, comprising one or more complementarity determining regions (CDRs) having at least one amino acid substitution in one or more CDRs of a heavy chain CDR, where the antibody or functional fragment thereof has specific binding activity for a cryptic collagen epitope. The invention also provides methods of using an antibody having specific binding activity for a cryptic collagen epitope, including methods of inhibiting angiogenesis, tumor growth, and metastasis.
    Type: Grant
    Filed: July 14, 2006
    Date of Patent: July 28, 2009
    Assignee: Cell-Matrix, Inc.
    Inventors: Jeffry D. Watkins, William D. Huse, Ying Tang, Daniel Broek, Peter Brooks
  • Methods for treating melanomas
    Patent number: 7566453
    Abstract: A therapeutic agent for myeloma comprising a combined use of a nitrogen mustard anticancer agent and anti-IL-6 receptor antibody. Thus, a therapeutic agent for myeloma comprising anti-IL-6 receptor antibody for use in combination with a nitrogen mustard anticancer agent; a therapeutic agent for myeloma comprising a nitrogen mustard anticancer agent for use in combination with anti-IL-6 receptor antibody; and a therapeutic agent for myeloma comprising a nitrogen mustard anticancer agent and anti-IL-6 receptor antibody.
    Type: Grant
    Filed: March 15, 2002
    Date of Patent: July 28, 2009
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Akito Nakamura, Kenichi Akamatsu
  • Humanized anti-CCR2 antibodies and methods of use therefor
    Patent number: 7566450
    Abstract: The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.
    Type: Grant
    Filed: October 26, 2007
    Date of Patent: July 28, 2009
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Gregory J. LaRosa, Christopher J. Horvath, Walter Newman, S. Tarran Jones, Siobhan H. O'Brien, Theresa O'Keefe
  • LAGE-1 tumor associated nucleic acids
    Patent number: 7563870
    Abstract: The invention describes the LAGE-1 tumor associated gene, including fragments, allelic variants and splice variants thereof. Also included are polypeptides and fragments thereof encoded by such genes, and antibodies relating thereto. Methods and products also are provided for diagnosing and treating conditions characterized by expression of a LAGE-1 gene product.
    Type: Grant
    Filed: June 25, 2004
    Date of Patent: July 21, 2009
    Assignee: Ludwig Institute for Cancer Research Ltd.
    Inventors: Bernard Lethé, Sophie Lucas, Charles De Smet, Daniele Godelaine, Thierry Boon-Falleur
  • Method of determining a chemotherapeutic regimen for non small cell lung cancer based on BRCA1 expression
    Patent number: 7563570
    Abstract: The present invention relates to a screening method for classifying patients and for selecting an effective chemotherapy for the treatment of a patient suffering from non-small-cell lung cancer (NSCLC), based on the use of his levels of BRCA1 expression to predict the outcome of chemotherapy.
    Type: Grant
    Filed: October 29, 2004
    Date of Patent: July 21, 2009
    Assignee: Pangaea Biotech
    Inventors: Rafael Rosell Costa, Miquel Taron Roca
  • Glycopeptides derived from pancreatic structures, antibodies and applications thereof in diagnostics and therapeutics
    Patent number: 7557193
    Abstract: The invention relates to a glycopeptide comprising between 1 and 40 repeated C-terminal polypeptides, with 11 amino acids, of BSDL or FAPP, whereby the aforementioned polypeptides are glycosylated and bear glycosylated epitopes giving rise to a specific immunological reaction with induced antibodies in a patient suffering from type 1 diabetes, and/or purified from biological fluids of human or animal origin or recombinant and produced by expression in a standard host cell comprising an enzymatic material necessary for priming a glycosylation, said host cell being genetically modified such as to comprise a gene coding for the aforementioned polypeptides and a gene coding for one or more enzymes selected from among glycosyltransferases and anti-glycopeptide antibodies. The invention also relates to the applications thereof in therapeutics and diagnostics.
    Type: Grant
    Filed: March 30, 2005
    Date of Patent: July 7, 2009
    Assignees: Universite de la Mediterranee, Institut National de la Sante et de la Recherche Medicale
    Inventors: Dominique Lombardo, Eric Mas, Marie-Odile Sadoulet, Laurence Panicot-Dubois, Jean-Paul Bernard
  • Vimentin directed diagnostics and therapeutics for multidrug resistant neoplastic disease
    Patent number: 7550256
    Abstract: Disclosed are methods for detecting multidrug resistance in neoplastic or damaged cells or multidrug resistant (MDR) neoplastic or damaged cells by detecting an increase in the cell surface expression of vimentin protein in such cells as compared to the level of cell surface expression of vimentin protein in a normal cell or a non-MDR neoplastic cell.
    Type: Grant
    Filed: December 15, 2003
    Date of Patent: June 23, 2009
    Assignee: Aurelium Biopharma, Inc.
    Inventors: Elias Georges, Lucile Serfass, Anne-Marie Bonneau, Frédéric Dallaire
  • Tumor rejection antigens
    Patent number: 7547439
    Abstract: Polypeptides comprising an unbroken sequence of amino acids from SEQ ID NO: 1 or 2, with an ability to complex with a major histocompatibility complex molecule type HLA-A2, and preferably HLA-A2.1.
    Type: Grant
    Filed: November 26, 1999
    Date of Patent: June 16, 2009
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Lan-Qing Huang, Aline Van Pel, Francis Brasseur, Etienne De Plaen, Thierry Boon
  • Systems for expressing toxic proteins, vectors and method of producing toxic proteins
    Patent number: 7544775
    Abstract: The present invention relates to a system for expressing toxic proteins, to an expression vector comprising this system, to a prokaryotic cell transformed with this system, and also to a method for synthesizing a toxic protein using this expression system. The expression system of the invention is characterized in that it comprises successively, in the 5?-3? direction, a nucleotide sequence encoding the Asp-Pro dipeptide and a nucleotide sequence encoding a toxic protein. According to a preferred embodiment of the invention, the expression system also comprises, upstream of the Asp-Pro sequence, a nucleotide sequence encoding a soluble protein. The expression system of the invention makes it possible to construct an expression vector that is useful for transforming a prokaryotic cell such as E. coli, for example in a method for synthesizing the toxic protein.
    Type: Grant
    Filed: September 19, 2003
    Date of Patent: June 9, 2009
    Assignee: Centre National de la Recherche Scientifique
    Inventors: Pierre Falson, François Penin, Cédric Montigny